TEVA Q2 2020 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-10.8% YoY

Gross Profit

$1.8B45.6% margin

Operating Income

$173M4.5% margin

Net Income

$140M3.6% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

-11.2%

Cash Flow

Operating Cash Flow

$273M

Free Cash Flow

$142M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$55.0B

Total Liabilities

$40.2B

Stockholders' Equity

$13.9B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.3B	-10.8%
Gross Profit	$1.8B	$1.9B	-6.9%
Operating Income	$173M	-$644M	+126.9%
Net Income	$140M	-$689M	+120.3%

Revenue Segments

Product

$3.3B86%

Distribution Service

$381M10%

Product and Service, Other

$141M4%

License

$22M1%

Geographic Segments

North America Segment

$2.0B58%

Europe Segment

$1.0B28%

International Markets

$488M14%